Literature DB >> 6800853

Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men.

R Z Sokol, A Palacios, L A Campfield, C Saul, R S Swerdloff.   

Abstract

Serum reproductive hormone levels were measured serially after eugonadal and hypogonadal men had received either a 200-mg or a 100-mg intramuscular injection of testosterone enanthate. The calculated mean integrated testosterone and estradiol levels indicated that the 200-mg testosterone enanthate injection in the hypogonadal subjects maintained eugonadal levels of these hormones through day 11. The 100-mg dose maintained eugonadal levels of these hormones through day 11. The 100-mg dose maintained eugonadal testosterone levels through day 7. The testosterone:estradiol ratios in both groups following the 200-mg injection remained above or at the eugonadal baseline trough day 21. The authors recommend that replacement therapy for hypogonadal men should be 200 mg of testosterone enanthate every 10 to 14 days. A similar dosage would be recommended if testosterone enanthate were to be used as an experimental inhibitor of spermatogenesis (contraceptive agent).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6800853     DOI: 10.1016/s0015-0282(16)46108-x

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  14 in total

Review 1.  Optimisation of treatment by applying programmable rate-controlled drug delivery technology.

Authors:  Yie W Chien; Senshang Lin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  An update on male hypogonadism therapy.

Authors:  Prasanth Surampudi; Ronald S Swerdloff; Christina Wang
Journal:  Expert Opin Pharmacother       Date:  2014-04-23       Impact factor: 3.889

Review 3.  Testosterone therapy in men: clinical and pharmacological perspectives.

Authors:  A Gambineri; R Pasquali
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

4.  Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets.

Authors:  M R Zacharin; G L Warne
Journal:  Arch Dis Child       Date:  1997-06       Impact factor: 3.791

Review 5.  Androgen replacement therapy: present and future.

Authors:  Louis J G Gooren; Mathijs C M Bunck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  New long-acting androgens.

Authors:  Louis J Gooren
Journal:  World J Urol       Date:  2003-10-09       Impact factor: 4.226

Review 7.  Androgen therapy in the aging male.

Authors:  Bruno Lunenfeld
Journal:  World J Urol       Date:  2003-10-24       Impact factor: 4.226

8.  Validation of a testosterone and dihydrotestosterone liquid chromatography tandem mass spectrometry assay: Interference and comparison with established methods.

Authors:  Christina Wang; Steve Shiraishi; Andrew Leung; Sima Baravarian; Laura Hull; Victor Goh; Paul W N Lee; Ronald S Swerdloff
Journal:  Steroids       Date:  2008-05-21       Impact factor: 2.668

9.  Androgen levels and sex functions in testosterone-treated hypogonadal men.

Authors:  L J Gooren
Journal:  Arch Sex Behav       Date:  1987-12

10.  Calcium and protein kinetics in prepubertal boys. Positive effects of testosterone.

Authors:  N Mauras; M W Haymond; D Darmaun; N E Vieira; S A Abrams; A L Yergey
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.